A clinical study to evaluate the biological effects of pre-operative intravenous administration of JX-594 (thymidine kinase-deactivated Vaccinia virus plus GM-CSF) prior to planned surgical resection of locally advanced/poor prognosis or metastatic cancers

Trial Profile

A clinical study to evaluate the biological effects of pre-operative intravenous administration of JX-594 (thymidine kinase-deactivated Vaccinia virus plus GM-CSF) prior to planned surgical resection of locally advanced/poor prognosis or metastatic cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Bladder cancer; Colorectal cancer; Liver cancer; Malignant melanoma; Renal cell carcinoma
  • Focus Pharmacokinetics
  • Acronyms Pre-Operative-JX594
  • Most Recent Events

    • 05 Jun 2018 Results (n=8) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2018 Results (N=9) presented in a Transgene media release.
    • 04 Jun 2018 According to a Transgene media release, the final data from this trial will be published in an upcoming paper
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top